T25:56片(14片×4片),140片(14片×10片)
制造供应商
日本化药 注:以上中文资料仅供参考,使用者以原资料为准。
完整说明资料附件: https://www.info.pmda.go.jp/go/pack/4229101F1042_1_08/
----------------------------------------------------------
NKS-1 is a prodrug of Fluorouracil(5-FU), an antineoplastic agent used as the treatment of various cancers such as advanced gastric and colorectal cancers.
It is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with Gimeracil and Oteracil, or along with Fluorouracil as NKS-1 T-uracil.
NKS-1 T is usually given in combination with other drugs that enhance the bioavailability of the 5-FU by blocking the enzyme responsible for its degradation, or serves to limit the toxicity of 5-FU by ensuring high concentrations of 5-FU at a lower dose of tegafur .
When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase(TS)during the pyrimidine pathway involved in DNA synthesis.
NKS-1 T is an antineoplastic agent that belongs in the class of pyrimidine analogues.It interferes with the 2'-deoxythymidylate(DTMP)synthesis in the pyrimidine pathway,resulting in inhibition of DNA synthesis .
In a phase III trial investigating the clinical efficacy of S-1(tegafur/gimeracil/oteracil) in patients with advanced or recurrent gastric cancer, treatment resulted in a high response rate and was associated with a longer overall survival and longer progression-free survival rate when used in combination with cisplatin.In a meta analysis, triple combination therapy consisting of tegafur, gimeracil and oteracil showed longer survival times and well tolerance in patients with advanced gastric cancer . NKS-1 T and its active metabolites are potent myleosuppressive agents.